Find link

language:

Find link is a tool written by Edward Betts.

searching for PD-L1 105 found (186 total)

alternate case: pD-L1

Cemiplimab (1,060 words) [view diff] exact match in snippet view article find links to article

that binds to the programmed death receptor-1 (PD-1), blocking the PD-1/PD-L1 pathway. The most common side effects include fatigue, rash, diarrhea, musculoskeletal

Interferon type I (2,934 words) [view diff] exact match in snippet view article find links to article

glioblastoma, medulloblastoma, astrocytoma, and melanoma. By combining PD-1/PD-L1 inhibitors with type I interferons, researchers aim to tackle multiple resistance

Tislelizumab (1,323 words) [view diff] exact match in snippet view article find links to article

treat people with locally advanced or metastatic urothelial carcinoma with PD-L1 high expression whose disease progressed during or following platinum-containing

Natural killer cell (9,227 words) [view diff] exact match in snippet view article find links to article

grade clones have been generated expressing the CARs for PD-L1, CD19, HER-2, and EGFR. PD-L1 targeted high affinity NK cells have been given to a number

BMS-202 (160 words) [view diff] exact match in snippet view article find links to article

BMS-202 is a small-molecule drug PD-L1 inhibitor developed by Bristol-Myers Squibb which displays significant anti-tumor activity against glioblastoma

ZG16 (2,023 words) [view diff] exact match in snippet view article find links to article

the lymph nodes. Since PD-L1 proteins are regulated by N-glycosylation, the ZG16 works to bind directly to glycosylated PD-L1 proteins through its lectin

Triple-negative breast cancer (3,423 words) [view diff] exact match in snippet view article find links to article

programmed death cell ligand 1 (PD-L1) protein or BRCA gene mutation. Also known as immunotherapy the presence of PD-L1 on cancer cells mates with an associate

Sacituzumab govitecan (2,429 words) [view diff] exact match in snippet view article find links to article

either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. It is also indicated for the treatment of people with unresectable

Ipilimumab (4,728 words) [view diff] exact match in snippet view article find links to article

with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (≥1%) as determined by an FDA-approved test. In October 2020, the U.S. FDA

Stromal cell (2,735 words) [view diff] exact match in snippet view article find links to article

contact-dependent mechanism is the expression of programmed death-ligand 1 (PD-L1), through which MSCs can suppress T cells. The secreted substances MSCs

Cosibelimab (399 words) [view diff] exact match in snippet view article find links to article

carcinoma. It is a human immunoglobulin G1 (IgG1) programmed death ligand-1 (PD-L1) blocking antibody. The most common adverse reactions include fatigue, musculoskeletal

Weiping Zou (877 words) [view diff] exact match in snippet view article find links to article

1038/s41586-019-1170-y (2019). Lin, H. et al. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J Clin Invest

Polypurine reverse-Hoogsteen hairpin (1,551 words) [view diff] exact match in snippet view article find links to article

CD47 in MCF7 breast cancer cells and SIRPα in macrophages, and the PD-1/PD-L1 pathway in human tumor cells. PPRHs can also be used as the capture probe

Timeline of immunology (2,182 words) [view diff] exact match in snippet view article find links to article

first described 2016 – A third class of immune checkpoint inhibitor, anti-PD-L1 (atezolizumab), is approved for the treatment of bladder cancer 2017 – First

Ming Tatt Cheah (632 words) [view diff] exact match in snippet view article find links to article

multiple drugs in different therapeutic areas, most recently for Tecentriq® (PD-L1 Ab), tiragolumb (TIGIT Ab), and ipatasertib (AKT inhibitor) in oncology

Jindřich Kopeček (2,548 words) [view diff] exact match in snippet view article find links to article

to “hot” ones that are susceptible to PD-L1 degradation immunotherapy. Original design of a new multivalent PD-L1 antagonist not only acts as a traditional

Jindřich Kopeček (2,548 words) [view diff] exact match in snippet view article find links to article

to “hot” ones that are susceptible to PD-L1 degradation immunotherapy. Original design of a new multivalent PD-L1 antagonist not only acts as a traditional

Adenocarcinoma of the lung (4,606 words) [view diff] exact match in snippet view article find links to article

standard of care for patients with advanced or metastatic NSCLC with high PD-L1 expression levels, and responses are even more pronounced for tumor with

Hypophysitis (605 words) [view diff] exact match in snippet view article find links to article

side-effect of the new immune checkpoint inhibitors of the CTLA-4 inhibitor and PD-L1 inhibitor classes, used for the treatment of melanoma, and should be considered

NK-92 (1,685 words) [view diff] exact match in snippet view article find links to article

number of cancer surface receptors such as programmed death domain ligand 1 (PD-L1), CD19 (a type of B cell receptor), human epidermal growth factor receptor

Atezolizumab/hyaluronidase (362 words) [view diff] exact match in snippet view article find links to article

soft part sarcoma. It contains atezolizumab, a programmed death-ligand 1 (PD-L1) blocking monoclonal antibody; and hyaluronidase (human recombinant), an

CimaVax-EGF (1,556 words) [view diff] exact match in snippet view article find links to article

were unlikely to benefit from nivolumab alone due to low tumor levels of PD-L1, suggesting that the combination may work better than either agent individually

Ravi Radhakrishnan (1,323 words) [view diff] exact match in snippet view article find links to article

PD-L1, influenced by IFN-γ, to suppress CD8 T cell function, correlating levels with patient response to anti-PD-1 therapy and suggesting exosomal PD-L1

Stromal cell-derived factor 1 (2,934 words) [view diff] exact match in snippet view article find links to article

urinary tract system, methylation of the CXCL12 promoter and expression of PD-L1 may be powerful prognostic biomarkers for biochemical recurrence in prostate

Douglas Fearon (483 words) [view diff] exact match in snippet view article find links to article

from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer". Proceedings of the National Academy

Affimer (2,484 words) [view diff] exact match in snippet view article find links to article

tissue penetration, for example in solid tumours where Avacta are developing PD-L1 inhibitors as alternatives to Opdivo and Yervoy, though requires half life

Blocking antibody (718 words) [view diff] exact match in snippet view article find links to article

longer-lived T-cells. The blocking antibody BMS-936559 has been shown to bind to PD-L1 and prevent its binding to PD-1. These new treatments are not without side-effects

Michal Schwartz (2,126 words) [view diff] exact match in snippet view article find links to article

immunotherapy by modestly blocking the inhibitory immune checkpoint PD1/PD-L1 pathway.[citation needed] This treatment drives an immune-dependent cascade

MedImmune (804 words) [view diff] exact match in snippet view article find links to article

many types of cancer. Major phase III trials included: durvalumab (anti-PD-L1) tremelimumab (anti-CTLA-4) moxetumomab pasudotox (anti-CD22) benralizumab

Nichole M. Danzl (407 words) [view diff] exact match in snippet view article find links to article

Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway". clic. Retrieved October 12, 2021. Echeverria, Adriana P.; Cohn

Erdafitinib (1,350 words) [view diff] exact match in snippet view article find links to article

alterations who had received 1-2 prior systemic treatments, including a PD-1 or PD-L1 inhibitor. Participants were randomized 1:1 to receive erdafitinib or investigator's

T cell (9,063 words) [view diff] exact match in snippet view article find links to article

with sepsis are associated with PD-1 or PD-L1 expression and can be restored by antibodies targeting PD-1 or PD-L1". Journal of Leukocyte Biology. 100 (6):

Selvigaltin (264 words) [view diff] exact match in snippet view article find links to article

"Resistance to anti-PD-1/anti-PD-L1: GB1211 reverses galectin-3 induced blockade of pembrolizumab and atezolizumab binding to PD-1/PD-L1". Journal of Clinical

TOX (1,814 words) [view diff] exact match in snippet view article find links to article

cells to evade the cytotoxic T cells through upregulated expression of PD-L1. Markers of effector functions that are decreased when TOX is overexpressed

Penpulimab (530 words) [view diff] exact match in snippet view article find links to article

the PD-1 receptor on T cells, preventing interaction with its ligands, PD-L1 and PD-L2. This blockade restores T-cell-mediated immune responses against

Tremelimumab (1,355 words) [view diff] exact match in snippet view article find links to article

mesothelioma. In a phase III trial, AstraZeneca paired tremelimumab with a PD-L1 inhibitor, durvalumab, for the first-line treatment of non-small cell lung

Adenosine A2A receptor (5,207 words) [view diff] exact match in snippet view article find links to article

pathway. The A2AR antogonist CPI-444 has shown this in combination with anti-PD-L1 or anti-CTLA-4 treatment as it eliminated tumors in up to 90% of treated

Retifanlimab (460 words) [view diff] exact match in snippet view article find links to article

PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1

Sarcomatoid carcinoma of the lung (835 words) [view diff] exact match in snippet view article find links to article

"Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)". Journal of Thoracic Oncology. 8 (6): 803–805. doi:10.1097/JTO.0b013e318292be18

Oncolytic adenovirus (4,201 words) [view diff] exact match in snippet view article find links to article

been genetically engineered to express checkpoint inhibitors (CTLA-4, anti-PD-L1 antibodies) to release brake of T-cell activity, and to express costimulatory

Transitional cell carcinoma (1,970 words) [view diff] exact match in snippet view article find links to article

either a programmed death receptor-1 (PD-1) or a programmed death-ligand 1 (PD-L1) inhibitor. Transitional cell carcinomas can also be associated with the

Lymphocyte-activation gene 3 (6,133 words) [view diff] exact match in snippet view article find links to article

plays a modulating role in autoimmune diabetes. Additionally, blocking PD-L1 and LAG-3 was identified as a potential therapeutic strategy for Plasmodium

Genentech (2,875 words) [view diff] exact match in snippet view article find links to article

one prior therapy. 2016: Tecentriq (atezolizumab): First-in-class anti-PD-L1 antibody for the treatment of advanced bladder cancer or metastatic non-small

Nivolumab/hyaluronidase (363 words) [view diff] exact match in snippet view article find links to article

PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1

Immunoglobulin heavy chain (1,710 words) [view diff] exact match in snippet view article find links to article

Tianyuzhou; Merlino, Glenn; Day, Chi-Ping; Ho, Mitchell (2021-07-21). "A novel PD-L1-targeted shark VNAR single domain-based CAR-T strategy for treating breast

The Hallmarks of Cancer (4,314 words) [view diff] exact match in snippet view article find links to article

death-1 ligand (PD-L1) on their surface.This protein is usually used to prevent T cells from attacking healthy cells. Tumor cells express PD-L1 in high amounts

The Hallmarks of Cancer (4,314 words) [view diff] exact match in snippet view article find links to article

death-1 ligand (PD-L1) on their surface.This protein is usually used to prevent T cells from attacking healthy cells. Tumor cells express PD-L1 in high amounts

Toll-like receptor 9 (2,590 words) [view diff] exact match in snippet view article find links to article

Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy (NASDAQ:DVAX)". investors.dynavax.com. Archived from the original

Toripalimab (640 words) [view diff] exact match in snippet view article find links to article

PD-L1 inhibitors PD-1 inhibitorsTooltip Programmed cell death protein 1 Nivolumab Pembrolizumab Cemiplimab Dostarlimab Retifanlimab Toripalimab PD-L1

Sotorasib (2,073 words) [view diff] exact match in snippet view article find links to article

previously treated with previous platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor. The study showed an improvement in the progression-free survival

Carla F. Kim (750 words) [view diff] exact match in snippet view article find links to article

"Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression". Cancer Cell. 25 (5): 590–604. doi:10.1016/j.ccr.2014.03.033

Primary mediastinal B-cell lymphoma (843 words) [view diff] exact match in snippet view article find links to article

rituximab). Other, more intense, regimens may be more effective. PD-1 and PD-L1 inhibitors can be used. Radiation therapy may be added, especially if chemotherapy

List of therapeutic monoclonal antibodies (4,236 words) [view diff] exact match in snippet view article find links to article

(CD62L) severely injured patients Atezolizumab Tecentriq mab humanized PD-L1 Y cancer Atidortoxumab mab human Staphylococcus aureus alpha toxin Atinumab

Angus W. Thomson (378 words) [view diff] exact match in snippet view article find links to article

Butterfield, Lisa H.; Metes, Diana M.; Thomson, Angus W. (January 2018). "High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic

James A. Wells (2,043 words) [view diff] exact match in snippet view article find links to article

PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1". Journal of the American Chemical Society. 143 (2): 593–598. doi:10.1021/jacs

Suzanne L. Topalian (813 words) [view diff] exact match in snippet view article find links to article

Program, Topalian researches modulating immune checkpoints such as PD-1 and PD-L1 in cancer therapy, and discovering biomarkers predicting clinical outcomes

Visceral leishmaniasis (9,201 words) [view diff] exact match in snippet view article find links to article

(2016). "Regulatory IgDhi B Cells Suppress T Cell Function Via IL-10 and PD-L1 during Progressive Visceral Leishmaniasis". J Immunol. 196 (10): 4100–9

Oligoclonal antibody (1,204 words) [view diff] exact match in snippet view article find links to article

and liquid). Most of them are targeting immune checkpoints (CTLA-4, PD1/PD-L1, ...). The only oligoclonal antibody treatment against immune checkpoint

Cytotoxic T-lymphocyte associated protein 4 (3,464 words) [view diff] exact match in snippet view article find links to article

T, Wu J, Tang Q, et al. (November 2009). "Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal". Nature Immunology

KLRG1 (1,599 words) [view diff] exact match in snippet view article find links to article

oncology has gained widespread interest (e.g., CTLA-4, PD-1, and its ligand PD-L1). Unlike the obvious enhanced immune activation present in CTLA-4 and PD-1

Gordon J. Freeman (287 words) [view diff] exact match in snippet view article find links to article

B7 gene family as well as of CD28 and CTLA-4 in T cell activation and of PD-L1 / PD-1 (programmed cell death protein 1) contribute to the inhibition of

Viralytics (2,428 words) [view diff] exact match in snippet view article find links to article

study, reported in June 2015, has shown tumour-infiltrating lymphocytes and PD-L1 upregulation in the area of the lesions, the latter phenomenon suggesting

Sejal Saglani (644 words) [view diff] exact match in snippet view article find links to article

2014). "Lung microbiota promotes tolerance to allergens in neonates via PD-L1". Nature medicine. 20 (6): 642–647. doi:10.1038/NM.3568. ISSN 1078-8956

Free fatty acid receptor (2,804 words) [view diff] exact match in snippet view article find links to article

Sui X, Gao Y (September 2021). "Dual Blockade of Lactate/GPR81 and PD-1/PD-L1 Pathways Enhances the Anti-Tumor Effects of Metformin". Biomolecules. 11

Ubiquitin ligase (4,432 words) [view diff] exact match in snippet view article find links to article

PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1". Journal of the American Chemical Society. 143 (2): 593–598. Bibcode:2021JAChS

Peter Fecci (2,322 words) [view diff] exact match in snippet view article find links to article

EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase levels of proinflammatory

CBLB (gene) (1,393 words) [view diff] exact match in snippet view article

C, MacDonald D, Arce F, Bennett CL, Collins M, Escors D (August 2011). "PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation

Small-cell carcinoma (4,965 words) [view diff] exact match in snippet view article find links to article

Nivolumab (Opdivo), a PD-1 inhibitor (2018) Atezolizumab (Tecentriq), a PD-L1 inhibitor (2018) Tarlatamab, a bi-specific T-cell engager (2024) Canadian

Immunotherapy (6,093 words) [view diff] exact match in snippet view article find links to article

with metastatic melanoma resistant to multiple immunotherapies. Anti-PD-1/PD-L1 and anti-CTLA-4 antibodies are the two types of checkpoint inhibitors currently

Adjuvant therapy (4,805 words) [view diff] exact match in snippet view article find links to article

such as the inhibitors to programmed death 1 (PD-1) and the PD-1 ligand PD-L1 are under way. In 2015, a comprehensive meta-analysis of 47 trials and 11

Antibody–drug conjugate (4,329 words) [view diff] exact match in snippet view article find links to article

locally advanced or metastatic urothelial cancer who have received a PD-1 or PD-L1 inhibitor, and a Pt-containing therapy Trastuzumab deruxtecan Enhertu AstraZeneca/Daiichi

Tissue-resident memory T cell (3,066 words) [view diff] exact match in snippet view article find links to article

Cells Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway". Cell Reports. 29 (12): 3916–3932.e5. doi:10.1016/j.celrep.2019

Opnurasib (414 words) [view diff] exact match in snippet view article find links to article

June 2023). "A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression". Journal of Clinical Oncology. 41 (16_suppl): TPS9158. doi:10

William Bachovchin (1,320 words) [view diff] exact match in snippet view article find links to article

single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding. Protein Expression and Purification, 177, 105766. Henderson, J

Acinic cell carcinoma (5,761 words) [view diff] exact match in snippet view article find links to article

infiltration, with CD8+ T-cells predominating in most cases Relatively low PD-L1 expression compared to other salivary gland malignancies Desmoplastic stromal

T helper cell (6,612 words) [view diff] exact match in snippet view article find links to article

IL-10-dependent way. Triggering PD-1 expressed on activated monocytes by its ligand PD-L1, induces IL-10 production which inhibits CD4 T-cell function. In coronavirus

Galectin-9 (2,173 words) [view diff] exact match in snippet view article find links to article

Shekarriz R, Asgarian-Omran H (August 2017). "Upregulation of Galectin-9 and PD-L1 Immune Checkpoints Molecules in Patients with Chronic Lymphocytic Leukemia"

Macrophage (10,341 words) [view diff] exact match in snippet view article find links to article

"Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1". Frontiers in Immunology. 12: 690869. doi:10.3389/fimmu.2021.690869

Single-domain antibody (3,905 words) [view diff] exact match in snippet view article find links to article

English H, Hong J, Liang T, Merlino G, Day CP, Ho M (March 2022). "A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating

Aggressive lymphoma (1,402 words) [view diff] exact match in snippet view article find links to article

and therapeutic blocking of programmed cell death protein 1 pathway (PD-1/PD-L1). While CAR T-cells have shown promising efficacy in patients with DLBCL

Julie Brahmer (857 words) [view diff] exact match in snippet view article find links to article

it can benefit those with lung cancer mutations with lower levels of the PD-L1 protein. Brahmer was also promoted to professor of oncology at the Johns

Cholangiocarcinoma (7,708 words) [view diff] exact match in snippet view article find links to article

Durvalumab, (Imfinzi) is an immune checkpoint inhibitor that blocks the PD-L1 protein on the surface of immune cells, thereby allowing the immune system

HAVCR2 (2,940 words) [view diff] exact match in snippet view article find links to article

Pharmaceuticals; TSR-022, Tesaro, Inc.) in combination with anti-PD-1 or anti-PD-L1 therapies are ongoing. HAVCR2 is also an exhaustion marker for NK cells

Cervical cancer (12,818 words) [view diff] exact match in snippet view article find links to article

this setting. Additional immunotherapy agents, including other PD-1 and PD-L1 inhibitors, are under investigation and have similarly shown encouraging

Lieping Chen (538 words) [view diff] exact match in snippet view article find links to article

Chair". NextCure. Retrieved 2 January 2024. Wu, Lei Lei (25 October 2022). "PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down

Microbubble (3,928 words) [view diff] exact match in snippet view article find links to article

Zhongqian; Wang, Chao; Yang, Jian; Zeng, Chuhui; Fan, Rui; Guo, Jinhe (2020). "PD-L1-targeted microbubbles loaded with docetaxel produce a synergistic effect

T-cell depletion (2,833 words) [view diff] exact match in snippet view article find links to article

Stephen; Martin, Paul; Chen, Yuan-Zhong; Wang, Jianmin; Zeng, Defu (2017). "PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor

MRNA-4157/V940 (901 words) [view diff] exact match in snippet view article find links to article

agent directed to stimulatory or coinhibitory T-cell receptor (e.g. PD-1, PD-L1, CTLA-4, et al.) are not allowed to enrolled in the study. mRNA-4157/V940

TMEM271 (922 words) [view diff] exact match in snippet view article find links to article

"Abstract 5668: DNA damage response gene mutations and their association with PD-L1 expression in sarcoma and bone tumor". Cancer Research. 82 (12_Supplement):

Reza Dana (2,712 words) [view diff] exact match in snippet view article find links to article

epithelium to maintain angiogenic privilege including the VEGFR-3 sink and PD-L1 mechanisms, (vi) developing strategies to promote corneal endothelial cell

Carla V. Rothlin (1,914 words) [view diff] exact match in snippet view article find links to article

Rothlin and her team found that Axl signalling induces the expression of PD-L1 on dendritic cells in the tumor microenvironment, supporting the TAM receptor

Globo H (1,999 words) [view diff] exact match in snippet view article find links to article

(2017-12-12). "Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer". Cancer Biomarkers. 21

Richter's transformation (4,783 words) [view diff] exact match in snippet view article find links to article

Gamaleldin MA, Ghallab OM, Nadwan EA, Abo Elwafa RA (November 2021). "PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection

CAR T cell (9,260 words) [view diff] exact match in snippet view article find links to article

Tianyuzhou; Merlino, Glenn; Day, Chi-Ping; Ho, Mitchell (2022-03-17). "A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating

Metronomic therapy (2,949 words) [view diff] exact match in snippet view article find links to article

the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma". British Journal

Cancer-associated fibroblast (3,599 words) [view diff] exact match in snippet view article find links to article

are suppressed by CAFs is high expression of checkpoint molecules such as PD-L1, PD-L2, B7-H3/H4, galactins and the enzyme IDO. CAFs in pancreatic cancer

Bruce Beutler (12,123 words) [view diff] exact match in snippet view article find links to article

"Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice". Proceedings of the National Academy of Sciences

POLD1 (7,954 words) [view diff] exact match in snippet view article find links to article

Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1" (PDF). JAMA Oncology. 1 (9): 1319–23. doi:10.1001/jamaoncol.2015.2151.

Eftilagimod alpha (2,722 words) [view diff] exact match in snippet view article find links to article

metastatic NSCLC Second-line metastatic NSCLC in patients refractory to PD-L1 or PD-1 therapies such as pembrolizumab, nivolumab, avelumab) Second-line

Radiomics (5,585 words) [view diff] exact match in snippet view article find links to article

assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study". The

The Cancer Genome Atlas (7,468 words) [view diff] exact match in snippet view article find links to article

infiltration or overexpressed immune checkpoint genes CTLA4, PD-1, and PD-L1 Pancreatic Ductal Adenocarcinoma 150 Used deep and targeted sequencing to

Innate lymphoid cell (10,509 words) [view diff] exact match in snippet view article find links to article

PMID 20644162. Heeren, A. Marijne, et al. "High and interrelated rates of PD-L1+ CD14+ antigen-presenting cells and regulatory T cells mark the microenvironment

RNA therapeutics (9,545 words) [view diff] exact match in snippet view article find links to article

X, Li S, Lu Y, et al. (April 2019). "Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release"

Physical oncology (6,739 words) [view diff] exact match in snippet view article find links to article

Sato, Mitsuo; Kondo, Masashi; Hasegawa, Yoshinori (2018). "Regulation of PD-L1 expression by matrix stiffness in lung cancer cells". Biochemical and Biophysical

Azaborine (3,769 words) [view diff] exact match in snippet view article find links to article

reported the synthesis of a boron-nitrogen containing isostere of a PD-1/PD-L1 inhibitor, an important class of molecules for cancer treatments. In 2011